Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Advanced Solid Tumors 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2mCRPC 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Fanconi Anemia, Complementation Group D1 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Adenocarcinoma 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Ovarian Cancer × talazoparib × Clear all
NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡